Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...

Infliximab injectable solution is available as brand-name drugs. It’s not available in a generic version. Brand names: Remicade, Inflectra, Renflexis. Infliximab comes in an injectable solution for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. After previously discontinuing infliximab, 35% of ...

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Learn everything you need to know about Infliximab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Infliximab is a monoclonal antibody that is administered intravenously to treat patients with chronic inflammatory diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque ...

Pyoderma gangrenosum is a chronic ulcerating skin disorder of unknown cause that develops in approximately 2% of patients with inflammatory bowel disease (IBD). Several case reports have indicated ...

Adalimumab (Humira, AbbVie), golimumab (Simponi, Merck Sharp & Dohme) and infliximab (Remicade, Merck Sharp & Dohme; Inflectra, Hospira; Remsima, Celltrion) are monoclonal antibodies that inhibit the ...

Infliximab and adalimumab, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease (see section 1.6) whose disease has not responded to ...